Phosphate-containing copolymers for virulence suppression
Assignee3M Innovative Properties Company
InventorsCarl A. Laskowski, Timothy M. Gillard, Ranjani V. Parthasarathy, Hannah C. Cohen, Max A. Kruziki
Life of this patent
Estimating the term…
Abstract
Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.
Claims20
A phosphate-containing copolymer comprising a first copolymeric unit comprising:
- (a) monomeric units of Formula (I) and
- (b) monomeric units of Formula (II) or a salt thereof and
- (c) optional monomeric units of Formula (III)
- wherein
- R1 is hydrogen, alkyl, aryl, alkaryl, or aralkyl;
- x is mole percent monomeric units of Formula (I) based on total moles of monomeric units in the first copolymeric unit;
- y is mole percent monomeric units of Formula (II) based on total moles of monomeric units in the first copolymeric unit;
- z is mole percent monomeric units of Formula (III) based on total moles of monomeric units in the first copolymeric unit;
- (x+y+2z) is at least 90 mole percent based on total moles of monomeric units in the first copolymeric unit;
- 100[(y+2z)÷(x+y+2z)] is in a range of 3.5 to 30 percent;
- and
- each asterisk (*) denotes a connection site to another monomeric unit or to a terminal group.
A medical composition comprising a phosphate-containing copolymer, wherein the medical composition is suitable for administration to a mammal and wherein the phosphate-containing copolymer comprises a first copolymeric unit comprising:
- (a) monomeric units of Formula (I) and
- (b) monomeric units of Formula (II) or a salt thereof and
- (c) optional monomeric units of Formula (III)
- wherein
- R1 is hydrogen, alkyl, aryl, alkaryl, or aralkyl;
- x is mole percent monomeric units of Formula (I) based on total moles of monomeric units in the first copolymeric unit;
- y is mole percent monomeric units of Formula (II) based on total moles of monomeric units in the first copolymeric unit;
- z is mole percent monomeric units of Formula (III) based on total moles of monomeric units in the first copolymeric unit;
- (x+y+2z) is at least 90 mole percent based on total moles of monomeric units in the first copolymeric unit;
- 100[(y+2z)÷(x+y+2z)] is in a range of 3.5 to 30 percent;
- and
- each asterisk (*) denotes a connection site to another monomeric unit or to a terminal group.
A method of suppressing microbial virulence, the method comprising administering and/or applying a medical composition, the medical composition comprising a phosphate-containing copolymer, the phosphate-containing copolymer comprising a first copolymeric unit comprising:
- (a) monomeric units of Formula (I) and
- (b) monomeric units of Formula (II) or a salt thereof and
- (c) optional monomeric units of Formula (III)
- wherein
- R1 is hydrogen, alkyl, aryl, alkaryl, or aralkyl;
- x is mole percent monomeric units of Formula (I) based on total moles of monomeric units in the first copolymeric unit;
- y is mole percent monomeric units of Formula (II) based on total moles of monomeric units in the first copolymeric unit;
- z is mole percent monomeric units of Formula (III) based on total moles of monomeric units in the first copolymeric unit;
- (x+y+2z) is at least 90 mole percent based on total moles of monomeric units in the first copolymeric unit;
- 100[(y+2z)÷(x+y+2z)] is in a range of 3.5 to 30 percent;
- and
- each asterisk (*) denotes a connection site to another monomeric unit or to a terminal group.
Dependencies are inferred from the claim text.